THBS2 and Hepatic fibrosis: On the other hand, the advent of SGLT2i has introduced a paradigm shift in the management of type 2 diabetes and HF, with several landmark randomized controlled trials showing consistent benefits in reducing the rates of HHF regardless of the presence of CVD and the status of LV function [14–18, 36–40] While we recently demonstrated that circulating TSP2 had the potential to become a novel prognostic marker of liver fibrosis in type 2 diabetes [41], our current findings further proposed that it might also be usefully employed for HF risk stratification in patients with type 2 diabetes.